Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients

References

• Feldman SR, Fleischer AB. Jr., Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis. 2011;87:201–7.
   PubMed Web of Science ®Google Scholar
• van der Geer S, Kleingeld PA, Snijders CC, et al. Development of a non-melanoma skin cancer detection model. Dermatology (Basel). 2015;230:161–9.
   PubMed Web of Science ®Google Scholar
• Ulrich M, Alarcon I, Malvehy J, Puig S. In vivo reflectance confocal microscopy characterization of field-directed 5-fluorouracil 0.5%/salicylic acid 10% in actinic keratosis. Dermatology (Basel). 2015;230:193–8.
   PubMed Web of Science ®Google Scholar
• Friis KB, Themstrup L, Jemec GB. Optical coherence tomography in the diagnosis of actinic keratosis – a systematic review. Photodiagnosis Photodyn Ther. 2017.
   PubMed Web of Science ®Google Scholar
• Boone MA, Suppa M, Marneffe A, et al. A new algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma based on in vivo analysis of optical properties by high-definition optical coherence tomography. J Eur Acad Dermatol Venereol. 2016;30:1714–25.
   PubMed Web of Science ®Google Scholar
• Olsen J, Themstrup L, De Carvalho N, et al. Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma. Photodiagnosis Photodyn Ther. 2016;16:44–9.
   PubMed Web of Science ®Google Scholar
• Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649–55.
   PubMed Web of Science ®Google Scholar
• Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991;127:1029–31.
   PubMed Web of Science ®Google Scholar
• Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23–4.
   PubMed Web of Science ®Google Scholar
• Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795–7.
   PubMed Web of Science ®Google Scholar
• Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131:455–64.
   PubMed Web of Science ®Google Scholar
• Harvey I, Frankel S, Marks R, et al. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer. 1996;74:1302–7.
   PubMed Web of Science ®Google Scholar
• Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154–9.
   PubMed Web of Science ®Google Scholar
• Naldi L, Chatenoud L, Piccitto R, et al. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003. Arch Dermatol. 2006;142:2004–722.
   Google Scholar
• Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.
   PubMed Web of Science ®Google Scholar
• Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2016.
   Web of Science ®Google Scholar
• Swedish Society for Dermatology and Venereology [Swedish: Svenska Sällskapet för Dermatologisk Kirurgi och Onkologi (SDKO)]. SDKO:s Riktlinjer för handläggning av skivepitelcancer och basalcellscancer - Reviderad version 2016. 2016 [August 25, 2016]. Available from: http://ssdv.se/images/pdf/SDKOs_Riktlinjer_for_SCC__BCC_2016.pdf.
   Google Scholar
• Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum – Short version. J Eur Acad Dermatol Venereol. 2015;29:2069–79.
   PubMed Web of Science ®Google Scholar
• Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2016;1–12.
   PubMed Web of Science ®Google Scholar
• Dansk Dermatologisk Selskab (DDS). DDS AK guidelines - Guidelines vedrørende behandling af aktiniske keratoser Udarbejdet for Dansk Dermatologisk Selskab. 2014. Available from: http://www.dds.nu/wp-content/uploads/2014/09/2014_DDS-guidelines-AK_Godkendt_2014-09-28.pdf. Accessed March 13, 2017.
   Google Scholar
• Augustin M, Tu JH, Knudsen KM, et al. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol. 2015;72:816–21.
   PubMed Web of Science ®Google Scholar
• Tennvall GR, Norlin JM, Malmberg I, et al. Health related quality of life in patients with actinic keratosis–an observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes. 2015;13:111.
   PubMed Web of Science ®Google Scholar
• Esmann S, Jemec GB. Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat. 2007;18:53–8.
   PubMed Web of Science ®Google Scholar
• Esmann S, Vinding GR, Christensen KB, Jemec GB. Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire. Br J Dermatol. 2013;168:277–83.
   PubMed Web of Science ®Google Scholar
• Gibbons E, Casanas I, Comabella C, Fitzpatrick R. A structured review of patient-reported outcome measures for patients with skin cancer, 2013. Br J Dermatol. 2013;168:1176–86.
   PubMed Web of Science ®Google Scholar
• Hanke WC, Norlin JM, Mark Knudsen K, et al. Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat. 2016;27:450–5.
   PubMed Web of Science ®Google Scholar
• Berlin JM. Current and emerging treatment strategies for the treatment of actinic keratosis. Clinical, cosmetic and investigational dermatology. CCID. 2010;3:119.
   Google Scholar
• Krawtchenko N, Roewert‐Huber J, et al. A randomised study of topical 5% imiquimod vs. topical 5‐fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‐year follow‐up. Br J Dermatol. 2007;157:34–40.
   PubMed Web of Science ®Google Scholar
• FASS. Available from: www.fass.se. Accessed June 3, 2016.
   Google Scholar
• Jim On SC, Knudsen KM, Skov T, Lebwohl M. Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel. Clin Cosmet Investig Dermatol. 2016;9:211–16.
   PubMed Web of Science ®Google Scholar
• Foley P, Stockfleth E, Peris K, et al. Adherence to topical therapies in actinic keratosis: A literature review. J Dermatolog Treat. 2016;27:538–45.
   PubMed Web of Science ®Google Scholar
• Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2013;8:35–41.
   PubMed Web of Science ®Google Scholar
• Erntoft S, Norlin JM, Pollard C, Diepgen TL. Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study. Br J Dermatol. 2016;175:1094–6.
   PubMed Web of Science ®Google Scholar
• Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68:S28–S38.
   PubMed Web of Science ®Google Scholar
• Bharmal M, Payne K, Atkinson MJ, et al. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8:S9–s24.
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
   PubMedGoogle Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;24:67–74.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Malotte CK, Choi P, et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q. 1990;17:253–67.
   PubMedGoogle Scholar
• Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43.
   PubMed Web of Science ®Google Scholar
• Devlin N, Shah K, Feng Y, et al. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England. Office of Health Economics (OHE) Research Paper. 2016.
   Google Scholar
• Erntoft S, Norlin JM, Pollard C, Diepgen TL. Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study. Br J Dermatol 2016;175:1094–6.
   PubMed Web of Science ®Google Scholar
• Hanke WC, Norlin JM, Knudsen KM, et al. Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat. 2016;27:450–5.
   PubMed Web of Science ®Google Scholar
• Pereira FR, Basra MK, Finlay AY, Salek MS. The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology (Basel). 2012;225:45–53.
   PubMed Web of Science ®Google Scholar